Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients. Issue 1 (7th January 2020)

• Record Type: Journal Article
• Authors: Cordonnier, Marine; Nardin, Charlée; Chanteloup, Gaëtan; Derangere, Valentin; Algros, Marie‐Paule; Arnould, Laurent; Garrido, Carmen; Aubin, François; Gobbo, Jessica
• Is Part Of: Journal of extracellular vesicles. Volume 9:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-07
• Subjects: Melanoma -- exosome -- PD‐L1/PD‐1 -- immune checkpoint -- follow‐up; Cells -- Mechanical properties -- Periodicals; Transport Vesicles; Cells -- Mechanical properties; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; Periodicals; 571.63
• DOI: 10.1080/20013078.2019.1710899
• Languages: English
• ISSNs: 2001-3078

Abstract

ABSTRACT: In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal‐PD‐L1 in melanoma patients' follow‐up. We studied the dynamics of exosomal‐PD‐L1 from 100 melanoma patients by using an enzyme‐linked immunosorbent assay. We found that PD‐L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD‐L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T‐cell activation. In plasma from melanoma patients, the level of PD‐L1 (n= 30, median 64.26 pg/mL) was significantly higher in exosomes compared to soluble PD‐L1 (n= 30, 0.1 pg/mL). Furthermore, exosomal‐PD‐L1 was detected in all patients whereas only 67% of tumour biopsies were PD‐L1 positive. Although baseline exosomal‐PD‐L1 levels were not associated with clinic‐pathologic characteristics, their variations after the cures (ΔExoPD‐L1) correlated with the tumour response to treatment. A ΔExoPD‐L1 cut‐off of> 100 was defined, yielding an 83% sensitivity, a 70% specificity, a 91% positive predictive value and 54% negative predictive values for disease progression. The use of the cut‐off allowed stratification in two groups of patients statistically different concerning overall survival and progression‐free survival. PD‐L1 levels in circulating exosomes seem to be a more reliable marker than PD‐L1 expression in tumour biopsies. Monitoring of circulating exosomal‐PD‐L1 may be useful to predict the tumour response to treatment and clinical outcome.